Follow FrankTwisk on Twitter  






Slechts 0,1%

van de mensen

voldoet aan

de Canadese kriteria

voor ME/CVS






Als we de resultaten van een recent onderzoek van Pheby en kollega's mogen doortrekken

Dat is heel wat anders dan 1 op 40 (2,5%) van mensen met "CVS" volgens de Reeves-kriteria!





Prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in three regions of England: a repeated cross-sectional study in primary care.

BMC Medicine 2011, 9:91. doi:10.1186/1741-7015-9-91.

Nacul LC, Lacerda EM, Pheby D, Campion P, Molokhia M, Fayyaz S, Leite, JCDC, Poland F, Howe A, Drachler ML.



Published: 28 July 2011




Abstract (provisional)





ME/CFS or chronic fatigue syndrome (CFS)

has been used to name a range of chronic conditions

characterized by extreme fatigue and other disabling symptoms.


Attempts to estimate the burden of disease have been limited

by selection bias, and

by lack of diagnostic biomarkers and of agreed reproducible case definitions.


We estimated the prevalence and incidence of ME/CFS

in three regions in England, and

discussed the implications of frequency statistics and

the use of different case definitions for

health and social care planning and for research.





We compared the clinical presentation, prevalence and incidence of ME/CFS

based in a sample of 143,000 individuals aged 18 to 64 years,

covered by primary care services in 3 regions of England.


Case ascertainment involved:

  1. electronic search for chronic fatigue cases;
  2. direct questioning of general practitioners (GPs)
  3. on cases not previously identified by the search;

  4. clinical review of identified cases
  5. according to CDC-1994, Canadian and Epidemiological Case (ECD) Definitions.

This enabled the identification of cases with high validity.





The estimated minimum prevalence rate of ME/CFS was

0.2% for cases meeting any of the study case definitions,

0.19% for the CDC-1994 definition,

0.11% for the Canadian definition and

0.03% for the ECD.


The overall estimated minimal yearly incidence was 0.015%.


The highest rates were found in London and the lowest in East Yorkshire.


All cases conforming to the Canadian criteria also met the CDC-1994 criteria

but presented higher prevalence and severity of symptoms.





ME/CFS is not uncommon in England and

represents a significant burden to patients and society.


The number of people with chronic fatigue

who do not meet specific criteria for ME/CFS

is higher still.


Both groups

have high levels of need for

service provision, including health and social care.


We suggest combining the use of

both the CDC-1994 and Canadian criteria

for ascertainment of ME/CFS cases,

alongside careful clinical phenotyping

of study participants.


This combination if used systematically will enable

international comparisons,

minimisation of bias, and

the identification and investigation of

distinct sub-groups of patients

with possibly distinct aetiologies and pathophysiologies,

standing a better chance of

translation into effective specific treatments.